Mortality from Coronavirus (Covid) SARS-CoV-2 in Oncological Patients
DOI:
https://doi.org/10.17533/udea.iatreia.312Keywords:
Hematology, Mortality, Neoplasms, SARS-CoV-2Abstract
Introduction: SARS-CoV-2 infection represents a special mortality risk for cancer patients.
Objective: is to identify and describe the clinical and pathological characteristics associated with mortality in cancer patients with SARS-CoV-2 infection.
Methods: a retrospective, cross-sectional and analytical study was conducted between June 2020 and April 2021 in three hemato oncological units.
Results: 274 patients with hematological or oncological malignancy who presented SARS-CoV-2 infection were identified, general mortality was 18.6%, variables like hematological neoplasia (p=0.026), solid neoplasia (p=0.021), leukemia (p=0.011), symptoms such as fever, dyspnea, general malaise, and odynophagia, comorbidities like moderate to severe renal disease (p =0.021), HIV infection (p=0.032) and type 2 diabetes mellitus (p=0.046) were related to mortality. The multivariate analysis showed that the presence of leukemia (OR 4.23, CI 1.10-16.0, P 0.035), dyspnea (OR 9.58, CI 3.59-25.3, P 0.001) and HIV infection (OR 16.5, CI 1.10-247, P 0.042) predict SARS-CoV-2 mortality in cancer patients.
Conclusion: Mortality from SARS-CoV-2 in cancer patients is higher than in the general population, being higher in patients with kidney disease, HIV, diabetes and hematological malignancies.
Downloads
References
(1) World Health Organization (WHO). Coronavirus disease (COVID-19) outbreak [Internet]. 2020. Disponible en: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
(2) Rozenfeld Y, Beam J, Maier H, Haggerson W, Boudreau K, Carlson J, et al. A model of disparities: Risk factors associated with COVID-19 infection. Int J Equity Health [Internet]. 2020;19(1):1–10. https://doi.org/10.1186/s12939-020-01242-z
(3) Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male [Internet]. 2020;23:1416–24. https://doi.org/10.1080/13685538.2020.1774748
(4) Asokan I, Rabadia SV, Yang EH. The COVID-19 Pandemic and its Impact on the Cardio-Oncology Population. Curr Oncol Rep [Internet]. 2020;22(6):60. https://doi.org/10.1007/s11912-020-00945-4
(5) Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med [Internet]. 2020;17(3):519-527. https://doi.org/10.20892/j.issn.2095-3941.2020.0289
(6) Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients with Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol [Internet]. 2020;6:1108–10. https://doi.org/10.1001/jamaoncol.2020.0980
(7) Burki TK. Cancer guidelines during the COVID-19 pandemic. Lancet Oncol [Internet]. 2020;21(5):629–30. https://doi.org/10.1016/S1470-2045(20)30217-5
(8) Kim R, Emi M, Tanabe K. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology [Internet]. 2006;119:254–64. https://doi.org/10.1111/j.1365-2567.2006.02430.x
(9) Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol [Internet]. 2020;21(7):914–22. https://doi.org/10.1016/S1470-2045(20)30314-4
(10) Salunke AA, Nandy K, Pathak SK, Shah J, Kamani M, Kottakota V, et al. Impact of COVID -19 in cancer patients on severity of disease and fatal outcomes: A systematic review and meta-analysis. Diabetes Metab Syndr Clin Res Rev [Internet]. 2020;14:1431–7. https://doi.org/10.1016/j.dsx.2020.07.037
(11) Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet [Internet]. 2020;395:565–74. https://doi.org/10.1016/S0140-6736(20)30251-8
(12) Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med [Internet]. 2020;382:1708–20. https://doi.org/10.1056/NEJMoa2002032
(13) Raymond E, Thieblemont C, Alran S, Faivre S. Impact of the COVID-19 Outbreak on the Management of Patients with Cancer. Target Oncol [Internet]. 2020;15:249–59. https://doi.org/10.1007/s11523-020-00721-1
(14) Lee LY, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet (London, England) [Internet]. 2020;395:1919–26. https://doi.org/10.1016/S0140-6736(20)31173-9
(15) Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol [Internet]. 2020;21(3):335–7. https://doi.org/10.1016/S1470-2045(20)30096-6
(16) NCCN. Coronavirus disease 2019 (COVID-19) resources for the cancer care community [Internet]. 2020. Available from: https://www.nccn.org/home/news/NewsDetails?NewsId=2025
(17) ESMO. What should medical oncologists know about COVID-19? [Internet]. 2020. Available from: https://www.esmo.org/covid-19-and-cancer
(18) Vecchione L, Stintzing S, Pentheroudakis G, Douillard JY, Lordick F. ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer. ESMO open [Internet]. 2020;5(Suppl 3):e000826. https://doi.org/10.1136/esmoopen-2020-000826
(19) ASCO. ASCO coronavirus resources [Internet]. 2020. Available from: https://old-prod.asco.org/covid-resources
(20) Gosain R, Abdou Y, Singh A, Rana N, Puzanov I, Ernstoff MS. COVID-19 and Cancer: a Comprehensive Review. Curr Oncol Rep [Internet]. 2020;22(5):53. https://doi.org/10.1007/s11912-020-00934-7
(21) Willan J, King AJ, Hayes S, Collins GP, Peniket A. Care of haematology patients in a COVID-19 epidemic. Br J Haematol [Internet]. 2020;189(2):241–3. https://doi.org/10.1111/bjh.16620
(22) Al-Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, et al. A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. Oncologist [Internet]. 2020;25(6):e936–45. https://doi.org/10.1634/theoncologist.2020-0213
(23) Cancarevic I, Tathineni P, Malik BH. Coronavirus Disease 2019 (COVID-19) in Cancer Patients. Cureus [Internet]. 2020;12(4):e7835. https://doi.org/10.7759/cureus.7835
(24) Jyotsana N, King MR. The Impact of COVID-19 on Cancer Risk and Treatment. Cell Mol Bioeng [Internet]. 2020;13(4):285–91. https://doi.org/10.1007/s12195-020-00630-3
(25) Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet [Internet]. 2020;395(10241):1907–18. https://doi.org/10.1016/S0140-6736(20)31187-9
(26) LeBlanc TW, Abernethy AP, Casarett DJ. What is different about patients with hematologic malignancies? A retrospective cohort study of cancer patients referred to a hospice research network. J Pain Symptom Manage [Internet]. 2015;49(3):505–12. https://doi.org/10.1016/j.jpainsymman.2014.07.003
(27) Krem MM, Nutalapati S, Latta HL, Thomas CZ, El-Haddad H, Vilchez GA, et al. Hematologic malignancy patients suffer higher mortality and morbidity from COVID-19 than solid tumor patients. J Clin Oncol [Internet]. 2021;39(15):e19048–e19048. https://doi.org/10.1200/JCO.2021.39.15_suppl.e1904
(28) Ospina AV, Bruges R, Mantilla W, Triana I, Ramos P, Aruachan S, et al. Impact of COVID-19 Infection on Patients with Cancer: Experience in a Latin American Country: The ACHOCC-19 Study. Oncologist [Internet]. 2021;26(10):e1761-e1773. https://doi.org/10.1002/onco.13861
(29) Khoury E, Nevitt S, Madsen WR, Turtle L, Davies G, Palmieri C. Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open [Internet]. 2022;5(5):E2210880. https://doi.org/10.1001/jamanetworkopen.2022.10880
(30) Bosso M, Thanaraj TA, Abu-Farha M, Alanbaei M, Abubaker J, Al-Mulla F. The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19. Mol Ther - Methods Clin Dev [Internet]. 2020;18:321–7. https://doi.org/10.1016/j.omtm.2020.06.017
(31) Eisinger RW, Lerner AM, Fauci AS. Human Immunodeficiency Virus/AIDS in the Era of Coronavirus Disease 2019: A Juxtaposition of 2 Pandemics. J Infect Dis [Internet]. 2021;224(9):1455–1461. https://doi.org/10.1093/infdis/jiab114
(32) Lamarche C, Iliuta IA, Kitzler T. Infectious Disease Risk in Dialysis Patients: A Transdisciplinary Approach. Can J Kidney Heal Dis [Internet]. 2019;6. https://doi.org/10.1177/2054358119839080
(33) Sawyers A, Chou M, Johannet P, Gulati N, Qian Y, Zhong J, et al. Clinical outcomes in cancer patients with COVID‐19. Cancer Rep [Internet]. 2021;4(6):e1413. https://doi.org/10.1002/cnr2.1413
(34) Ozer M, Goksu SY, Mahdi M, Gandhi N. Characteristics and outcomes of cancer patients with covid-19 at a safety-net hospital. Cancer Treat Res Commun [Internet]. 2021;28:100418. https://doi.org/10.1016/j.ctarc.2021.100418
(35) Asghar K, Abu-Bakar M, Akram MJ, Farooq A, Siddique K, Rana IA, et al. Clinical Characteristics of COVID-19-Infected Cancer Patients in Pakistan: Differences Between Survivors and Non-Survivors. Front Oncol [Internet]. 2021;11:1–9. https://doi.org/10.3389/fonc.2021.655634
(36) Lima A, Sousa H, Nobre A, Faria AL, Machado M. The Impact of COVID-19 Pandemic in Portuguese Cancer Patients: A Retrospective Study. Int J Environ Res Public Health [Internet]. 2021;18(16):8552. https://doi.org/10.3390/ijerph18168552
(37) Hingmire S, Wategaonkar R, Hegde S, Mekha M, Kulkarni R, Rajbhoj A, et al. Outcome of COVID-19 Infection in Cancer Patients in Pune. South Asian J Cancer [Internet]. 2021; 10(1):23-27. https://doi.org/10.1055/s-0041-1731910
(38) Assaad S, ZroSunba P, Cropet C, Blay JY, ONCOVID-19 study Consortium. Mortality of patients with solid and haematological cancers presenting with symptoms of COVID-19 with vs without detectable SARS-COV-2: a French nationwide prospective cohort study. Br J Cancer [Internet]. 2021;125(5):658-671. https://doi.org/10.1038/s41416-021-01452-4
(39) Lièvre A, Turpin A, Ray-Coquard IL, Le-Malicot K, Thariat J, Ahle G, et al. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19). Eur J Cancer [Internet]. 2020;141:62-81. https://doi.org/10.1016/j.ejca.2020.09.035
(40) Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol [Internet]. 2020; 21(10):1309-1316. https://doi.org/10.1016/S1470-2045(20)30442-3
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Iatreia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Papers published in the journal are available for use under the Creative Commons license, specifically Attribution-NonCommercial-ShareAlike 4.0 International.
The papers must be unpublished and sent exclusively to the Journal Iatreia; the author uploading the contribution is required to submit two fully completed formats: article submission and authorship responsibility.
